These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34864911)

  • 1. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
    Nash P; Richette P; Gossec L; Marchesoni A; Ritchlin C; Kato K; McDearmon-Blondell EL; Lesser E; McCaskill R; Feng D; Anderson JK; Ruderman EM
    Rheumatology (Oxford); 2022 Aug; 61(8):3257-3268. PubMed ID: 34864911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
    Mease PJ; Lertratanakul A; Anderson JK; Papp K; Van den Bosch F; Tsuji S; Dokoupilova E; Keiserman M; Wang X; Zhong S; McCaskill RM; Zueger P; Pangan AL; Tillett W
    Ann Rheum Dis; 2021 Mar; 80(3):312-320. PubMed ID: 33272960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
    Mease P; Setty A; Papp K; Van den Bosch F; Tsuji S; Keiserman M; Carter K; Li Y; McCaskill R; McDearmon-Blondell E; Wung P; Tillett W
    Clin Exp Rheumatol; 2023 Nov; 41(11):2286-2297. PubMed ID: 37404160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
    Burmester GR; Van den Bosch F; Tesser J; Shmagel A; Liu Y; Khan N; Camp HS; Kivitz A
    J Rheumatol; 2024 Jul; 51(7):663-672. PubMed ID: 38621793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V; Tundia N; Wells A; Buch MH; Radominski SC; Camp HS; Friedman A; Suboticki JL; Dunlap K; Goldschmidt D; Bergman M
    Rheumatology (Oxford); 2021 Jul; 60(7):3209-3221. PubMed ID: 33313898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
    Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F
    N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
    McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
    RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
    Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
    McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Haaland D; Chen L; Duan Y; Liu J; Lippe R; Wung P
    Rheumatol Ther; 2023 Feb; 10(1):275-292. PubMed ID: 36243812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM
    Rheumatol Ther; 2024 Jul; ():. PubMed ID: 39031276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
    Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study.
    Luchetti Gentiloni MM; Paci V; Carletto A; Zabotti A; Ramonda R; Chimenti MS; Dagna L; Luciano N; Piccinelli A; Giovannini I; Striani G; Boffini N; Sandri G; Possemato N; Pantano I; Benfaremo D; Salvarani C; Ciccia F; Selmi C; Moroncini G
    Arthritis Res Ther; 2023 Oct; 25(1):196. PubMed ID: 37821952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.